Peder Walberg appointed as interim Chief Medical Officer
January 20, 2021
Stockholm, Sweden, January 20, 2021. Egetis Therapeutics AB (publ) (ticker: EGTX) today announced that Peder Walberg will assume the role of interim Chief Medical Officer. He replaces Stefan Carlsson who has decided to leave the company to pursue other opportunities.
Peder Walberg takes on the position as interim CMO in addition to his current part time role within the company with focus on business development and the continued clinical development of the company’s lead candidate drug, Emcitate®. Peder will also continue as a member of the Board of Directors.
“The process to find a permanent CMO has been initiated. I want to take the opportunity to thank Stefan for the dedicated and professional job he has done for PledPharma and Egetis as a CMO”, said Egetis Therapeutics CEO Nicklas Westerholm.